Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 29;27(6):1114-1118.
doi: 10.5603/RPOR.a2022.0112. eCollection 2022.

Atypical responses to neoadjuvant chemotherapy combined with accelerated partial breast tumor-directed radiotherapy: two cases and considerations for future clinical trials

Nhu Hanh To  1   2   3   4 , Myriam Kossai  5   6 , Nabila Ouidir  7 , Noemie Grellier  1 , Elias Assaf  8 , Isabelle Gabelle-Flandin  9 , Yazid Belkacemi #  1   2   3   4   10 , Nina Radosevic-Robin #  5   6   10
Affiliations

Atypical responses to neoadjuvant chemotherapy combined with accelerated partial breast tumor-directed radiotherapy: two cases and considerations for future clinical trials

Nhu Hanh To et al. Rep Pract Oncol Radiother. .
No abstract available

Keywords: exceptional response; neoadjuvant; p53/pRb; radiotherapy; triple-negative breast cancer.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest The authors have no conflict of interest to declare.

Figures

Figure 1
Figure 1
Dynamics of the neutrophil/lymphocyte ratio (A) and the platelet-lymphocyte ratio (B) and thoughout the clinical follow-up. APBI — accelerated partial breast irradiation; ExR — the exceptional responder patient; ExNR — the exceptional non-responder patient
Figure 2
Figure 2
Histological and immunohistochemical characteristics of patients’ pre-treatment biopsies and post-treatment surgical specimens. A. ExR patient, pre-treatment, immunohistochemistry (IHC) for p53, × 200; B. ExR patient, pre-treatment, IHC for pRb, × 200; C. ExR patient, post-treatment, axillary lymph node, hyaline change, H&E, × 40; D. ExNR patient, pre-treatment, IHC for p53, × 200; E. ExNR patient, pre-treatment, IHC for pRb, × 200; F. ExNR patient, post-treatment, an area of HER2 score 2, IHC for HER2, × 200
See this image and copyright information in PMC

References

    1. Ho AY, Wright JL, Blitzblau RC, et al. Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists. Int J Radiat Oncol Biol Phys. 2020;108(1):227–241. doi: 10.1016/j.ijrobp.2020.05.011. - DOI - PMC - PubMed
    1. Corradini S, Krug D, Meattini I, et al. Preoperative radiotherapy: A paradigm shift in the treatment of breast cancer? A review of literature. Crit Rev Oncol Hematol. 2019;141:102–111. doi: 10.1016/j.critrevonc.2019.06.003. - DOI - PubMed
    1. Lehmann BD, Bauer JA, Chen Xi, et al. Identification of human triple-negative breast cancer subtypes and pre-clinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–2767. doi: 10.1172/JCI45014. - DOI - PMC - PubMed
    1. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10. doi: 10.1016/j.immuni.2013.07.012. - DOI - PubMed
    1. Knappskog S, Berge EO, Chrisanthar R, et al. Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo. Mol Oncol. 2015;9(8):1553–1564. doi: 10.1016/j.molonc.2015.04.008. - DOI - PMC - PubMed

LinkOut - more resources